drugset / Trial / NCT07104916

Mindfulness-based Psilocybin Therapy for PTSD

NCT07104916

Phase 2 Recruiting 30 enrolled Anthony P King Ohio State University · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomized, controlled study in participants with PTSD. The study will investigate the changes in brain activity, connectivity, and microstructural neuroplasticity assessed using EEG/EMG and multimodal MRI measures after administration of one oral dose of psilocybin, accompanied either with standard "psychological support" only; or with standard support plus Mindfulness-based Cognitive Therapy (MBCT).

Timeline

Start
2026-07-01
Primary completion
2029-09
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral